Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Helix BioPharmaHBPCF 28 3-Year Book Growth Rate is 185.80% as of Apr. 2026. GuruFocus rates HBPCF with a GF Score™ of 28/100. Among 1,131 Biotechnology companies, Helix BioPharma ranks better than 99.38% on this metric.
During the past 3 years, the average Book Value per Share Growth Rate was 185.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Helix BioPharma was 185.80% per year. The lowest was -35.10% per year. And the median was -9.25% per year.
Helix BioPharma (OTCPK:HBPCF) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Helix BioPharma 3-Year Book Growth Rate Related Terms
HBPCF vs VRTX, REGN, RVMD: 3-Year Book Growth Rate Comparison
For the Biotechnology subindustry, Helix BioPharma's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helix BioPharma 3-Year Book Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Helix BioPharma's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Helix BioPharma's 3-Year Book Growth Rate falls into.
Helix BioPharma 3-Year Book Growth Rate Calculation
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 185.80% mean?
Helix BioPharma (HBPCF) has a 3-Year Book Growth Rate of 185.80% as of Apr. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Helix BioPharma and its competitors. According to the industry distribution chart, Helix BioPharma ranks #7 out of 1131 companies in the Biotechnology industry, placing it in the top 0.59999999999999%.
Is Helix BioPharma's 3-Year Book Growth Rate too high?
Helix BioPharma's current 3-Year Book Growth Rate is 185.80%. Based on the distribution chart, Helix BioPharma ranks #7 out of 1131 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Helix BioPharma has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Helix BioPharma's 3-Year Book Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helix BioPharma ranks #7 out of 1131 companies for 3-Year Book Growth Rate. This places Helix BioPharma in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Biotechnology company?
A good 3-Year Book Growth Rate depends on the Biotechnology industry context. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Helix BioPharma and its competitors. Helix BioPharma's current 3-Year Book Growth Rate is 185.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helix BioPharma stock overvalued right now?
Helix BioPharma (HBPCF) has a current 3-Year Book Growth Rate of 185.80%. The current 3-Year Book Growth Rate is 185.80%. Helix BioPharma's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Helix BioPharma (HBPCF), the current 3-Year Book Growth Rate is 185.80% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.
28GF Score
Get the complete analysis for HBPCF
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HBPCF has been successfully added to your 
